Label: GUAIFENESIN EXTENDED RELEASE 600 MG- guaifenesin tablet
GUAIFENESIN EXTENDED RELEASE 1200 MG- guaifenesin tablet

  • NDC Code(s): 49483-723-50, 49483-724-70
  • Packager: TIME CAP LABORATORIES, INC.
  • Category: HUMAN OTC DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated February 7, 2024

If you are a consumer or patient please visit this version.

View All Sections
  • OTC - ACTIVE INGREDIENT SECTION

    For 600 mg:           
    Active ingredient (in each extended-release tablet)

    Guaifenesin, USP 600 mg


    For 1200 mg:
    Active ingredient (in each extended-release tablet)

    Guaifenesin, USP 1200 mg

  • OTC - PURPOSE SECTION

    Purpose

    Expectorant


  • INDICATIONS & USAGE SECTION

    Uses

    • helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive

  • WARNINGS SECTION

  • OTC - DO NOT USE SECTION

    Do not use

    • for children under 12 years of age

  • OTC - ASK DOCTOR SECTION

    Ask a doctor before use if you have

    • persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema
    • cough accompanied by too much phlegm (mucus)

  • OTC - STOP USE SECTION

    Stop use and ask a doctor if

    • cough lasts more than 7 days, comes back, or occurs with fever, rash, or persistent headache. These could be signs of a serious illness.
  • OTC - PREGNANCY OR BREAST FEEDING SECTION

    If pregnant or breast-feeding,ask a health professional before use.

  • OTC - KEEP OUT OF REACH OF CHILDREN SECTION

    Keep out of reach of children.In case of overdose, get medical help or contact a Poison Control Center (1-800-222-1222) right away.

  • DOSAGE & ADMINISTRATION SECTION

    Directions

    For 600 mg

    • do not crush, chew, or break extended - release tablet
    • take with a full glass of water
    • this product can be administered without regard for the timing of meals
    • adults and children 12 years of age and over: 1 or 2 extended - release tablets every 12 hours. Do not exceed 4 extended - release tablets in 24 hours.
    • children under 12 years of age: do not use


    For 1200 mg

    • do not crush, chew, or break extended - release tablet
    • take with a full glass of water
    • this product can be administered without regard for the timing of meals
    • adults and children 12 years of age and over: 1 extended - release tablet every 12 hours. Do not exceed 2 extended - release tablets in 24 hours.
    • children under 12 years of age: do not use


  • STORAGE AND HANDLING SECTION

    Other information

    • store at 20-25°C (68-77°F)

  • INACTIVE INGREDIENT SECTION

    Inactive ingredientscolloidal silicon dioxide, copovidone, FD&C blue No. 1 aluminum lake, hypromellose, magnesium stearate, maltodextrin, microcrystalline cellulose, povidone (K-30), sodium starch glycolate, stearic acid

  • OTC - QUESTIONS SECTION

    Questions or comments? Call 1-877-290-4008

  • PRINCIPAL DISPLAY PANEL

    guaifenesin-1200mg-70ct-labelguaifenesin-600mg-500ct-label

  • INGREDIENTS AND APPEARANCE
    GUAIFENESIN EXTENDED RELEASE 600 MG 
    guaifenesin tablet
    Product Information
    Product TypeHUMAN OTC DRUGItem Code (Source)NDC:49483-723
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    GUAIFENESIN (UNII: 495W7451VQ) (GUAIFENESIN - UNII:495W7451VQ) GUAIFENESIN600 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    COPOVIDONE K25-31 (UNII: D9C330MD8B)  
    HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MALTODEXTRIN (UNII: 7CVR7L4A2D)  
    MICROCRYSTALLINE CELLULOSE 102 (UNII: PNR0YF693Y)  
    POVIDONE K30 (UNII: U725QWY32X)  
    SODIUM STARCH GLYCOLATE TYPE A (UNII: H8AV0SQX4D)  
    STEARIC ACID (UNII: 4ELV7Z65AP)  
    FD&C BLUE NO. 1 ALUMINUM LAKE (UNII: J9EQA3S2JM)  
    Product Characteristics
    Colorwhite (Blue and White) Scoreno score
    ShapeOVALSize16mm
    FlavorImprint Code 42
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:49483-723-50500 in 1 BOTTLE; Type 0: Not a Combination Product01/08/2024
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21778001/08/2024
    GUAIFENESIN EXTENDED RELEASE 1200 MG 
    guaifenesin tablet
    Product Information
    Product TypeHUMAN OTC DRUGItem Code (Source)NDC:49483-724
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    GUAIFENESIN (UNII: 495W7451VQ) (GUAIFENESIN - UNII:495W7451VQ) GUAIFENESIN1200 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MALTODEXTRIN (UNII: 7CVR7L4A2D)  
    MICROCRYSTALLINE CELLULOSE 102 (UNII: PNR0YF693Y)  
    POVIDONE K30 (UNII: U725QWY32X)  
    SODIUM STARCH GLYCOLATE TYPE A (UNII: H8AV0SQX4D)  
    STEARIC ACID (UNII: 4ELV7Z65AP)  
    FD&C BLUE NO. 1 ALUMINUM LAKE (UNII: J9EQA3S2JM)  
    COPOVIDONE K25-31 (UNII: D9C330MD8B)  
    Product Characteristics
    Colorwhite (Blue and White) Scoreno score
    ShapeCAPSULESize22mm
    FlavorImprint Code 41
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:49483-724-7070 in 1 BOTTLE; Type 0: Not a Combination Product01/08/2024
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21778001/08/2024
    Labeler - TIME CAP LABORATORIES, INC. (037052099)
    Registrant - TIME CAP LABORATORIES, INC. (037052099)
    Establishment
    NameAddressID/FEIBusiness Operations
    MARKSANS PHARMA LIMITED925822975manufacture(49483-724, 49483-723)
View All Sections

Find additional resources

(also available in the left menu)

Safety

Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk

Related Resources

Medline Plus, Clinical Trials, PubMed, Biochemical Data Summary

More Info on this Drug

View Labeling Archives, RxNorm, Get Label RSS Feed, View NDC Code(s)NEW!